GLUE
Monte Rosa Therapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.39 EPS, $5.63M rev
Last earnings -2.8% on 2026-05-07
$21.46
▲ +3.61%$20.71▲ +353.17%
over 1Y
L $4.19EODHDH $25.31
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+3.6%
1W+16.6%
1M+7.9%
3M+40.7%
YTD+35.3%
1Y+353.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Buy
Revenue grew 63.5% YoY; but unprofitable (net margin -31.2%).
Monte Rosa Therapeutics, Inc. shows $124M in FY2025 revenue (+63.5% YoY), a -31.2% net margin, and -16.6% ROE.
Sources: SEC EDGAR (CIK 0001826457, latest 10-Q filed 2026-05-07) · EODHD · as of 6/24/2026, 3:12:52 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.